Legal & General Group
INDV icon

Legal & General Group’s Indivior Pharmaceuticals INDV Stock Holding History

Legal & General Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9M Sell
266,360
-24,984
-9% -$906K ﹤0.01% 1123
2026
Q1 		$8.88M Sell
291,344
-16,306
-5% -$539K ﹤0.01% 1178
2025
Q4 		$10.8M Buy
307,650
+172,129
+127% +$5.26M ﹤0.01% 1126
2025
Q3 		$2.74M Sell
135,521
-512,042
-79% -$10.7M ﹤0.01% 1853
2025
Q2 		$9.5M Sell
647,563
-117,849
-15% -$1.37M ﹤0.01% 1219
2025
Q1 		$7.18M Buy
765,412
+49,492
+7% +$520K ﹤0.01% 1323
2024
Q4 		$9.18M Buy
715,920
+19,542
+3% +$201K ﹤0.01% 1225
2024
Q3 		$6.88M Sell
696,378
-236,574
-25% -$2.77M ﹤0.01% 1407
2024
Q2 		$14.6M Buy
932,952
+919,745
+6,964% +$16.6M ﹤0.01% 943
2024
Q1 		$283K Buy
13,207
+280
+2% +$5.26K ﹤0.01% 2622
2023
Q4 		$195K Buy
12,927
+7,919
+158% +$141K ﹤0.01% 2703
2023
Q3 		$109K Buy
+5,008
New +$114K ﹤0.01% 2820

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legal & General Group's INDV Position: Q2 2026 in Review

Legal & General Group reduced its Indivior Pharmaceuticals (INDV) stake by 8.6% in Q2 2026, selling an estimated $906K and leaving 266,360 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1123.

Legal & General Group first reported a position in INDV in Q3 2023 and has held it in 12 quarters since. The position peaked at $14.6M in Q2 2024. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Legal & General Group held 266,360 shares of Indivior Pharmaceuticals worth $10.9M as of Q2 2026.
  • Legal & General Group sold 24,984 Indivior Pharmaceuticals shares in Q2 2026, an estimated $906K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1123 holding.
  • Legal & General Group first reported a position in Indivior Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Legal & General Group's Indivior Pharmaceuticals position peaked at $14.6M in Q2 2024.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.